


Figure 1A




Figure 1B




Figure 1C




Figure 1D




Figure 1E




Figure 2A




Figure 2D




Figure 2C





Figure 2B



Corneal pocket assay

Figure 2E



Control
20 hr - control IgG
5 min - Anti-Nrp2[8]
20 hr - Anti-Nrp2[8]
Neuropilin-2
VEGFR2
VEGFR3
% of Maximum
LEC FACS analysis

Figure 3A

Figure 3B




Figure 3C





Figure 3D



Nrp2/VEGFR3 binding assay data
IP with nrp-2
blot with R3

interaction blocked by a-Nrp2^B

Figure 3E




Figure 4A




Figure 4B




Figure 4C




Figure 4D



Figure 4E




Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 5E




Figure 5F




Figure 5G



Figure 5H




Figure 6A




Figure 6B



Figure 6C





Figure 6D




C6 tumor cell FACS analysis

Figure 6E




Figure 6F



66c14 - Vascular density

Figure 7A



66c14- Lymphatic density

Figure 7B




Lymphatic area
(LYVE-1) (%)
Control
VEGFR3 ECD
Anti-Nrp2B
Vascular area (PECAM) (%)
Control
VEGFR3 ECD
Anti-Nrp2B
LYVE-1
PECAM
Control
VEGFR3 ECD
Anti-Nrp2B

Figure 7C


Control
Anti-Nrp2^B
Harvest 1
Harvest 2
Tumor Volume (mm^3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
Days



Harvest 1
Harvest 2
Control
Control
Anti-Nrp2B
Anti-Nrp2B

Figure 7D

Figure 8A




Figure 8B



Figure 8C




Figure 8D





Figure 8E






Figure 9A




Figure 9B




Figure 9C




Figure 9D




Figure 9E




Figure 9F

Anti-NRP2B YW68.4.2 hIgG1 P1 file

DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSA
SFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTK
VEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV
TKSFNRGECEVQLVESGGGLVQPGGSLRLSCAASGFTITSSGIHWVRQAPG
KGLEWVARITPYDGSTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA
VYYCARYRGTLLFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
SPGK

Figure 10A

Anti-NRP2B YW68.4.2.36 hIgG1 P1 file

DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSA
SFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTK
VEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV
TKSFNRGECEVQLVESGGGLVQPGGSLRLSCAASGFTITSSGIHWVRQAPG
KGLEWVARITPYDGSTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA
VYYCARYRGRLLFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
SPGK

Figure 10B

Anti-NRP2A YW126.20 hIgG1 P1 file

DIQMTQSPSSLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYGAS
SRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQRYSYPITFGQGTKV
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT
KSFNRGECEVQLVESGGGLVQPGGSLRLSCAASGFSFSSRRMSWVRQAPG
KGLEWVSIINPYNGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTA
VYYCARSGPGQFGSTGYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKLYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTREVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
TQKSLSLSPGK

Figure 11



Light Chain Variable Domain Sequence Alignment of Anti-panNRP2A YW126.20
Kabat - CDR L1
Chothia - CDR L1
Contact - CDR L1
Kabat - CDR L2
Chothia - CDR L2
Contact - CDR L2
Kabat - CDR L3
Chothia - CDR L3
Contact - CDR L3
Kabat#
huKl
YW126.20

Figure 12

Heavy Chain Variable Domain Sequence Alignment of Anti-panNRP2A YW126.20






Figure 13




Lymphatic endothelial cell FACS analysis

Supp. Figure 1




Supp. Figure 2B




Supp. Figure 2A

Supp. Figure 3A




Proliferation assay



Miles Assay


Supp. Figure 3B




Supp. Figure 4A



Supp. Figure 4B



Supp. Figure 5A



Supp. Figure 5B